94 related articles for article (PubMed ID: 22843927)
1. The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial.
Schwarzlose-Schwarck S; Scholz CW; Regierer AC; Martus P; Neumann C; Habbel P; Liu H; Zang C; Schefe JH; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 Aug; 32(8):3435-41. PubMed ID: 22843927
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
6. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
Natale RB
Semin Oncol; 1995 Dec; 22(6 Suppl 15):34-7. PubMed ID: 8643968
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Amato RJ; Flaherty AL; Stepankiw M
Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
19. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
